Cargando…
GLI1: A Therapeutic Target for Cancer
GLI1 is a transcriptional effector at the terminal end of the Hedgehog signaling (Hh) pathway and is tightly regulated during embryonic development and tissue patterning/differentiation. GLI1 has low-level expression in differentiated tissues, however, in certain cancers, aberrant activation of GLI1...
Autores principales: | Avery, Justin T., Zhang, Ruowen, Boohaker, Rebecca J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186314/ https://www.ncbi.nlm.nih.gov/pubmed/34113570 http://dx.doi.org/10.3389/fonc.2021.673154 |
Ejemplares similares
-
GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAF(V600E) Colorectal Cancer
por: Zhang, Ruowen, et al.
Publicado: (2020) -
Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma
por: Cox, Amanda, et al.
Publicado: (2022) -
Circular RNA DGKB Promotes the Progression of Neuroblastoma by Targeting miR-873/GLI1 Axis
por: Yang, Jiale, et al.
Publicado: (2020) -
PRKCI Mediates Radiosensitivity via the Hedgehog/GLI1 Pathway in Cervical Cancer
por: Wu, Zhuna, et al.
Publicado: (2022) -
Hedgehog−Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1
por: Wang, Qian, et al.
Publicado: (2022)